12.86
0.22 (1.74%)
| Penutupan Terdahulu | 12.64 |
| Buka | 12.78 |
| Jumlah Dagangan | 361,137 |
| Purata Dagangan (3B) | 743,020 |
| Modal Pasaran | 218,059,504 |
| Harga / Pendapatan (P/E TTM) | 4.54 |
| Harga / Jualan (P/S) | 3.00 |
| Harga / Buku (P/B) | 4.62 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -7.57 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 333.06% |
| Nisbah Semasa (MRQ) | 4.71 |
| Aliran Tunai Operasi (OCF TTM) | -65.65 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -48.59 M |
| Pulangan Atas Aset (ROA TTM) | -33.79% |
| Pulangan Atas Ekuiti (ROE TTM) | -267.20% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Q32 Bio Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.00 |
|
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body’s first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 6.57% |
| % Dimiliki oleh Institusi | 73.27% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Monimus Capital Management, Lp | 31 Mar 2026 | 134,310 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |